Key facts
- Kestrel Therapeutics’s last known valuation is $17.7M (Jan 2022).
- It has raised $20.7M across 3 recorded rounds; the latest was Early Stage VC ($5.0M) in Jul 2025.
- Notable investors include Harvard Innovation Launch Lab, S32, Cormorant Asset Management, Pfizer Ventures, Santé Ventures.
- Kestrel Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Aug 2025 ($5.0M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Kestrel Therapeutics
Funding rounds
3 roundsAbout Kestrel Therapeutics
Developer of oncological drugs designed to treat RAS-driven cancers and bring a new therapy to cancer's frequently mutated oncogenic target. The company develops molecules active regardless of RAS isoform, mutation, or tumor histology, enabling healthcare professionals to cure patients suffering from cancer.
- Sector
- Healthcare
- HQ
- Allston, MA, United States
- Founded
- 2020
- Employees
- 28
- Website
- kestreltherapeutics.com/
- Ownership
- Privately Held (backing)
Kestrel Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kestrel Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kestrel Therapeutics in its N-PORT filings yet. We sweep new filings monthly.